- UCL research helps paralysed man to recover function
- Stenting safe and effective for long-term stroke prevention
- Department of Clinical & Experimental Epilepsy re-designated as a WHO Collaborating Centre
- Leonard Wolfson Experimental Neurology Centre open evening
- Brain stimulation to improve cognition in dementia
- Professor Lees receives Jay Van Andel Award for Outstanding Research in Parkinson’s Disease
- Creating brain cells from skin to study Alzheimer's
- Queen Square authors prominent in Brain collection of classic articles
- Toxic proteins implicated in frontotemporal dementia and motor neurone disease
- GCH1 gene and Parkinson’s risk
- Double mutation linked to frontotemporal dementia
- Equation to predict happiness
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia
- Researchers test whether diabetes drug can help Parkinson’s patients
- Acute optic neuritis: a review and proposed protocol
- Hippocampal subfield size predicts the precision of memory recall
- Immune system implicated in dementia development
- UCL and Chiesi Group announce partnership to develop a novel therapeutic for birth asphyxia
- Professor Golay made a Fellow of the ISMRM
- The new Leonard Wolfson Experimental Neurology Centre (LWENC) has opened for clinical studies and trials
- Professor Rees wins UCLU Student Choice Teaching Award
- New epilepsy treatment offers ‘on demand’ seizure suppression
- Professor Tabrizi and Professor Price elected to Fellowship of the Academy of Medical Sciences.
- Professor Dolan and Professor Friston elected to EMBO membership
- Vitamin B3 treatment for ataxia shows promise in first human trial
- Teaching Awards 2014
- Light-activated neurons from stem cells restore function to paralysed muscles
- UCL and Max Planck Society invest €5m to open world’s first computational psychiatry centre
- Successful launch of new annual leading edge neurology course
- Statins could help control MS
- Professor Hardy awarded Thudichum Medal by Biochemical Society
- Population Screening for vCJD Using a Novel Blood Test
- Chief Medical Officer appoints Professor Rossor as NIHR National Director for Dementia Research
- New partnership between UCLP brain tumour scientists and Brain Tumour Research
- Professor Hardy awarded Dan David Prize for work on the amyloid gene encoding APP
- NIHR award £650,000 for research into rare neurodegenerative and neuromuscular diseases
- Lowering levels of toxic protein reverses abnormalities in cells from patients with Huntington's disease
- Major initiative in understanding synaptic basis of neuropsychiatric disease
- Visit to the Berlin School of Mind and Brain
- Institute of Neurology ranked as the world’s top institution for epilepsy research.
- Predicting age at onset in SCA1 : does size matter?
- UCL takes the lead with £8.5m funding for dementia research
- Secretary of State visits leading dementia research projects
- Riboflavin Treatment for Childhood onset Motor Neuron Disease
- Dreading pain can be worse than pain itself
- Different gene expression in male and female brains helps explain differences in brain disorders
- New £20m centre pioneers first-in-man trials for neurodegenerative diseases
- RNA build-up linked to dementia and motor neuron disease
- Researchers estimate one in 2,000 people in the UK carry variant CJD proteins
- Professor Alan Thompson discusses Atlas of MS on Lancet News
- Wellcome Trust Principal Fellowship award to explore neural coding with the tripartite synapse
- Marsden's Book of Movement Disorders wins Neurology first prize at the 2013 BMA Book Awards
- Scientists develop refined diagnostic tool for inherited dementias
- Genetic mutations linked to Parkinson's Disease
- P-glycoprotein over-activity and drug resistance in temporal lobe epilepsy
- New Yale-UCL collaboration in brain aneurysm genetics
- ‘Risky’ stroke prevention procedure may be safe in some patients
- The Michael J. Fox Foundation awards grant for Exenatide research
- Institute Professor leads cross-disciplinary study on use of glucose in detecting cancer.
- Irreversible tissue loss seen within 40 days of spinal cord injury
- From Bedside to Bench in the Institute’s MRC Centre for Neuromuscular Diseases
- Centralising acute stroke services has saved more than 400 lives since 2010
- Rapid Response Innovation Award from The Michael J. Fox Foundation
- Predicting Language Outcome and Recovery After Stroke (PLORAS) project launches new website
- BRC awards over £500k to neuroscience projects
- ABTA Winners
- Diabetes drug could help treat Parkinson's Disease
- Clinical trials are vital tools in stroke research
- New gene identified for Dominant Congenital Spinal Muscular Atrophy and Hereditary Spastic Paraparesis
- Teaching Awards 2013
- 14th Annual Queen Square Symposium
- TRACK-HD study identifies early predictors of disease progression in Huntington’s disease
- The Great Brain Experiment: crowdsourcing data on how we think and act
- Psychogenic diseases linked to abnormal brain activity
- Human Brain Project wins major EU funding
- Gene mutation causes familial form of cranio-cervical dystonia
- Professor Ray Dolan awarded prestigious Klaus Joachim Zülch Prize
- Professor Dimitri Kullmann elected Editor of Brain
- IoN News Archive (2012)
- IoN News Archive (2011)
- IoN News Archive (2010)
- IoN News Archive (2009)
Published: Oct 2, 2014 2:43:57 PM
Published: Oct 10, 2014 5:54:41 PM
Published: Oct 22, 2014 9:52:00 AM
Published: Sep 16, 2013 1:37:21 PM
Published: Feb 24, 2014 2:53:53 PM
Published: Oct 9, 2014 12:19:36 PM
Published: Oct 9, 2014 12:14:46 PM
Predicting age at onset in SCA1 : does size matter?
18 December 2013
Research at the UCL Institute of Neurology, led by Paola Giunti, and the MRC National Institute for Medical Research, and published in the journal PloS Genetics, has shown how the length and the nature of gene repeat expansions affects spinocerebellar ataxia type 1 (SCA1).
These findings are significant for the genetic counselling and prognosis of people with SCA1 and were not possible with conventional diagnostic techniques.
At least nine of inherited neurodegenerative disorders, including Huntington’s disease share similar genetic causes and molecular mechanisms. They all involve a fault in their respective genes that consists of sections of the gene (CAG repeat) that repeat an abnormal number of times.
It is has been shown that patients with a longer number of repeats generally have a more severe condition and an earlier age at onset. In some patients, however, this is not the case, but the reason why was unknown.
This research team found that 11% of people with SCA1 have “interruptions” – short sections that break up the repeat expansions in the affected gene, ATXN1.
The research team was able to develop a genetic screening test that allowed them to divide their SCA1 patients into two groups based on whether or not their expanded repeat stretches in the ATXN1 gene contained an interruption.
In the participant sub-group, with interruptions, the research team found that their age at symptom onset is better predicted by the longest stretch of uninterrupted repeats rather than by the overall repeat length (including interruptions), as has previously been done.
“We recommend that diagnostic laboratories should use enzyme analysis to identify the presence of interruptions in expanded alleles,” said Dr Giunti.
“If an interruption is present, sequencing will allow better prediction of the age at onset in these patients. In addition, the diagnostic service at UCLH is currently looking into amending their repeat sizing calculations to account for the differences observed by the two different methods.”
This information will be important both for people who have ataxia and for people at risk of ataxia. It will be useful in diagnosis and counselling, particularly with respect to predicting people’s age at onset and the progression of their condition, as well as the probability of further genetic repeat expansion when transmitted to future generations.
In respect to the latter Dr Paola Giunti, lead author said:
“The interruption acts as a stabiliser, which is important as it is known that having the interruption will preclude further expansion in future generations, as the mutation in polyglutamine diseases is unstable through generations”.
“Without the contribution of the BRC, this research would not have been possible. With continued support, polyglutamine diseases can be looked at on the basis of this study, and here at UCL and UCLH we are in a privileged position to be able to do so”.
Menon, P.R. et al. (2013) The Role of Interruptions in polyQ in the Pathology of SCA1. PLoS Genetics, 9(7), e1003648. DOI: 10.1371/journal.pgen.1003648
Page last modified on 17 dec 13 09:34